Atossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lilly drugProactive Investors • 04/15/24
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerGlobeNewsWire • 04/15/24
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare ConferenceGlobeNewsWire • 04/11/24
Atossa Therapeutics reports positive data from breast cancer treatment trialProactive Investors • 04/09/24
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-EndoxifenGlobeNewsWire • 04/09/24
Atossa Therapeutics sets sights on breast cancer trial results after strong quarter of clinical milestonesProactive Investors • 04/01/24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 04/01/24
Atossa Therapeutics' breast cancer drug milestone sparks investor enthusiasmProactive Investors • 03/20/24
Atossa Therapeutics reports successful five-year treatment outcome for breast cancer patient using (Z)-endoxifenProactive Investors • 03/19/24
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer PatientGlobeNewsWire • 03/19/24
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing RequirementsGlobeNewsWire • 03/18/24
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of DirectorsGlobeNewsWire • 03/12/24
Atossa Therapeutics to present data from ongoing Phase 2 breast cancer trialProactive Investors • 03/06/24
Atossa Therapeutics doses first patient with (Z)-endoxifen in Phase 2 breast cancer trialProactive Investors • 02/22/24
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS StudyGlobeNewsWire • 02/22/24
Atossa Therapeutics' ‘standalone and superior drug' Z-endoxifen for breast cancer seen boosting shares by 300%Proactive Investors • 02/12/24
Atossa Therapeutics achieves patient enrollment milestone for Phase 2 breast cancer trialProactive Investors • 02/07/24
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical TrialGlobeNewsWire • 02/07/24
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the MarketInvestorPlace • 01/16/24
Atossa Therapeutics CEO dialogue between doctors and patients about breast density in 2024Proactive Investors • 01/09/24
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 12/08/23